Abstract 47P
Background
Studies have shown disparities in management of older patients with breast cancer, resulting in undertreatment. Older patients with co-morbidities pose a challenge for cancer care providers who must balance the risk of death due to toxicity from treatment versus the benefit of standard multimodality treatment. The aim of the study was to evaluate whether the sequencing of chemotherapy and surgery impact the ability to deliver both modalities of treatment.
Methods
A retrospective analysis of prospective data was evaluated between 2018 and 2022. We included patients >60 years of age with chronic comorbidities, with a clinical stage T1c-3 and N0-3, HER2-positive or triple-negative invasive breast cancer treated with chemotherapy alone, surgery alone, or both surgery and chemotherapy. Kaplan-Meier curves were plotted to compare the survival outcomes. Statistical analysis was done using SPSS v25.
Results
A total of 821 patients met the inclusion criteria, of whom 85.9% (N=705) underwent surgery as the initial treatment. Among patients who received chemotherapy first (N=116), 73.3% (N=85) were able to complete subsequent surgery. Factors associated with completion surgery after chemotherapy were younger age and clinical node-negative status. Among patients treated with surgery first, only 36.3% (N=256) received adjuvant chemotherapy. Among patients who received both modalities of treatment (N=341), women with more advanced stage tumors and those diagnosed in recent years were more likely to receive neoadjuvant chemotherapy. With a median follow-up of 19.3 months, cN0 patients who underwent both surgery and chemotherapy had significantly better overall survival compared to patients who received single modality of treatment.
Conclusions
In older, triple-negative or HER2-positive breast cancer patients with comorbidities, receipt of chemotherapy and surgery was associated with improved survival. Neoadjuvant chemotherapy group were twice as likely to receive both modalities of treatment than those undergoing surgery first. A multidisciplinary approach to evaluate geriatric patients with comorbidities is essential to deliver appropriate treatment and improve outcomes in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract